An Open Label, Single-arm, Phase 2 Study of Neoadjuvant Nivolumab and Nab-paclitaxel Before Radical Cystectomy for Patients With Muscle-invasive Bladder Cancer
Latest Information Update: 10 Sep 2024
At a glance
- Drugs Nivolumab (Primary) ; Paclitaxel (Primary)
- Indications Bladder cancer; Carcinoma; Urogenital cancer
- Focus Therapeutic Use
- Acronyms NURE-Combo
- 06 May 2024 Results (n=31) assessing safety and efficacy of of NIVO+ABX followed by RC and adjuvant NIVO in pts with MIBC presented at the 119th Annual Meeting of the American Urological Association
- 06 May 2024 Results of Impact of Neoadjuvant Chemo-Immunotherapy on Intra and Post Operative Outcomes in Patients with Bladder Cancer , presented at the 119th Annual Meeting of the American Urological Association
- 27 Jan 2024 First results (n=31) assessing safety and efficacy of neoadjuvant nivolumab (NIVO) and nab-paclitaxel (ABX) followed by postsurgical adjuvant NIVO in patients (pts) with muscle-invasive bladder cancer presented at the 2024 Genitourinary Cancers Symposium